This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
3tl5
From Proteopedia
(Difference between revisions)
m (Protected "3tl5" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
'''Unreleased structure''' | '''Unreleased structure''' | ||
| - | The entry 3tl5 is ON HOLD | + | The entry 3tl5 is ON HOLD until Paper Publication |
Authors: Murray, J.M., Wiesmann, C. | Authors: Murray, J.M., Wiesmann, C. | ||
Description: Discovery of GDC-0980: a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor for the Treatment of Cancer | Description: Discovery of GDC-0980: a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor for the Treatment of Cancer | ||
Revision as of 08:40, 30 October 2011
Unreleased structure
The entry 3tl5 is ON HOLD until Paper Publication
Authors: Murray, J.M., Wiesmann, C.
Description: Discovery of GDC-0980: a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor for the Treatment of Cancer
